Open AccessAtezolizumab-induced anaphylactic shock in a patient with hepatocellular carcinoma undergoing immunotherapy: A case report
Author(s) -
Liping Bian,
Chao Zheng,
Xiaolan Shi
Publication year - 2021
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v9.i16.4110
Subject(s) - medicine , anaphylactic shock , atezolizumab , hepatocellular carcinoma , immunotherapy , anaphylaxis , nivolumab , oncology , surgery , gastroenterology , immunology , allergy , cancer
Atezolizumab is a programmed death ligand 1 (PD-L1) inhibitor, and its combination with bevacizumab has been proven an effective immunotherapy for unresectable hepatocellular carcinoma (HCC). Treatment with immune checkpoint inhibitors (ICIs) can lead to hypersensitivity reactions; however, anaphylactic shock is rare. We present a case of life-threatening anaphylactic shock during atezolizumab infusion and performed a relevant literature review.